معرفی
Prof. Dr. Klaus Schulze-Osthoff is a leading faculty member at the University of Tübingen, affiliated with the Faculty of Science and leading a research group under Interfaculty Facilities. His work focuses on molecular mechanisms of apoptosis, cellular senescence, and NF-κB signaling, with strong translational applications in cancer and inflammatory diseases such as psoriasis and liver fibrosis.
- University: University of Tübingen
- School: Faculty of Science
- Department: Interfaculty Facilities
- Academic Rank: Professor
- Email: kso@uni-tuebingen.de
- Lab Affiliation: German Cancer Research Center (DKFZ Fellow)
Research Interests: His lab investigates key cellular processes including apoptosis, senescence, DNA damage response, stem cell reprogramming, and inflammation. Research spans from basic molecular mechanisms to clinical applications, particularly in oncology and autoimmune disorders. The group employs advanced techniques in molecular and cell biology, including RNAi, gene expression profiling, and live-cell imaging.
Publication Trends: His recent work emphasizes the role of IκBζ and NF-κB in inflammatory skin diseases like psoriasis, DNA damage quantification methods (e.g., LORD-Q), and the interplay between cellular senescence and cancer. There is a strong focus on identifying novel therapeutic targets and biomarkers for cancer and liver diseases.
Scientific Awards:
- Innovation Grant, University of Tübingen (2013)
- DKFZ Fellow (2013)
Advising and Grants: Prof. Schulze-Osthoff actively mentors multiple PhD and MSc students. His research is funded by major organizations including the Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe, Federal Ministry of Education and Research, Baden-Württemberg Foundation, and the Excellence Initiative of the University of Tübingen.
Labs and Research Networks: His lab is embedded in several key research networks, including the DNA Damage & Repair Service Unit, SFB 685 and 773, International Graduate School 1302, Comprehensive Cancer Center Tübingen, and the German Consortium for Translational Cancer Research (DKTK).
